British Patient Capital Commits €25m to Nauta Capital’s fifth fund
Press release
British Patient Capital announces a €25m commitment to the Nauta Tech Invest V Fund, as Nauta Capital announces its final close today at €190m. Investing from late seed and Series A, the fund has already invested in 11 companies in verticals including Fintech, Insurtech, Retailtech, and Open Source, among others.
Nauta Capital specialises in capital-efficient early-stage B2B software companies. The firm’s main areas of interest include SaaS solutions with strong network effects, vertically focused enterprise tech with the potential to transform large industries as well as those leveraging deeptech applications to solve challenges faced by large enterprises.
This investment by British Patient Capital to Nauta’s fifth fund follows its previous commitments to Nauta’s fourth fund, and its ‘Sidecar’ fund dedicated to backing Nauta’s existing later-stage portfolio companies.
We are excited to extend our relationship with Nauta through our anchor investment to their fifth fund. Businesses today are constantly challenged to enhance processes, increase productivity and improve employee wellbeing. This creates a significant opportunity for innovative B2B software companies, and the potential for compelling returns for their investors. Nauta is well placed to identify, back, and then support the growth of these types of high-growth companies. Judith Hartley CEO, British Patient Capital
At €190m this is our biggest fund to date, and one of Europe’s largest B2B funds, giving us the ability to follow on at later stages. British Patient Capital has been instrumental in this fundraising, and we are grateful for their continued trust in us and our investment strategy. Carles Ferrer General Partner, Nauta
Further Information
Notes to editors
About British Patient Capital
British Patient Capital is the trading name of British Patient Capital Limited, a wholly-owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. It forms part of the British Business Bank’s commercial arm.
Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large scale businesses. Launched in June 2018, British Patient Capital has £2.5bn to invest over 10 years in venture and venture growth capital to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up. Find out more at britishpatientcapital.co.uk.
British Business Bank plc and its principal operating subsidiaries are not banking institutions and do not operate as such. Neither British Business Bank nor its principal operating subsidiaries are authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA). A complete legal structure chart for British Business Bank plc and its subsidiaries can be found on the British Business Bank plc website.
British Patient Capital makes commitments and invests on its own behalf and on behalf of third-party investors whose investments British Patient Capital manages.
The investment from British Patient Capital into Nauta Tech Invest V does not amount to any endorsement or warranty from British Patient Capital, the British Business Bank plc, or the government of the UK.
About Nauta Capital
Nauta Capital is a pan-European Venture Capital firm investing in early-stage technology companies, with offices in London, Barcelona. and Berlin. With over half a billion assets under management and a team of 24 people, Nauta Capital is one of Europe’s largest B2B focused VCs.
As a sector-agnostic investor, Nauta’s main areas of interest include B2B SaaS solutions with strong network effects, vertically focused enterprise tech transforming large industries as well as those leveraging deep-tech applications to solve challenges faced by large enterprises. Nauta has backed more than 60 companies across Europe and exited 12.
Quick links
Latest news
-
Read more about British Patient Capital announces £8m investment into Tokamak Energy as part of $125m financing round Press release
20 November 2024 -
Read more about British Patient Capital – Full Year Results for the period ending 31 March 2024 Press release
04 November 2024 -
Read more about British Patient Capital announces £8m investment into Nuclera as part of a $75m Series C financing round Press release
16 October 2024